456 related articles for article (PubMed ID: 27347925)
21. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications.
Cooper ME
Am J Hypertens; 2004 Nov; 17(11 Pt 2):16S-20S; quiz A2-4. PubMed ID: 15539106
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin-(1-9) reduces cardiovascular and renal inflammation in experimental renin-independent hypertension.
Gonzalez L; Novoa U; Moya J; Gabrielli L; Jalil JE; García L; Chiong M; Lavandero S; Ocaranza MP
Biochem Pharmacol; 2018 Oct; 156():357-370. PubMed ID: 30179588
[TBL] [Abstract][Full Text] [Related]
24. Molecular Interactions of Arterial Hypertension in Its Target Organs.
Kućmierz J; Frąk W; Młynarska E; Franczyk B; Rysz J
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575833
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
Susic D; Varagic J; Frohlich ED
Am J Physiol Heart Circ Physiol; 2010 Apr; 298(4):H1177-81. PubMed ID: 20118410
[TBL] [Abstract][Full Text] [Related]
26. New approaches to blockade of the renin-angiotensin-aldosterone system: overview of regulation of the renin-angiotensin-aldosterone system.
Nishiyama A; Kim-Mitsuyama S
J Pharmacol Sci; 2010; 113(4):289-91. PubMed ID: 20675960
[TBL] [Abstract][Full Text] [Related]
27. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
Karalliedde J; Viberti G
J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
[TBL] [Abstract][Full Text] [Related]
28. Brain Angiotensinergic Regulation of the Immune System: Implications for Cardiovascular and Neuroendocrine Responses.
Iovino M; Messana T; De Pergola G; Iovino E; Guastamacchia E; Licchelli B; Vanacore A; Giagulli VA; Triggiani V
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):15-24. PubMed ID: 31237219
[TBL] [Abstract][Full Text] [Related]
29. Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system.
Simko F; Stanko P; Repova K; Baka T; Krajcirovicova K; Aziriova S; Domenig O; Zorad S; Adamcova M; Paulis L
Biomed Pharmacother; 2024 Apr; 173():116391. PubMed ID: 38461685
[TBL] [Abstract][Full Text] [Related]
30. Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.
Drapala A; Sikora M; Ufnal M
J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):250-8. PubMed ID: 25037529
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?
Emdin M; Fatini C; Mirizzi G; Poletti R; Borrelli C; Prontera C; Latini R; Passino C; Clerico A; Vergaro G
Clin Chim Acta; 2015 Mar; 443():85-93. PubMed ID: 25445411
[TBL] [Abstract][Full Text] [Related]
32. Prenatal exposure to angiotensin II increases blood pressure and decreases salt sensitivity in rats.
Svitok P; Senko T; Panakova Z; Olexova L; Krskova L; Okuliarova M; Zeman M
Clin Exp Hypertens; 2017; 39(6):489-494. PubMed ID: 28737438
[TBL] [Abstract][Full Text] [Related]
33. Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in
Simko F; Baka T; Poglitsch M; Repova K; Aziriova S; Krajcirovicova K; Zorad S; Adamcova M; Paulis L
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30282928
[TBL] [Abstract][Full Text] [Related]
34. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
Remuzzi G; Perico N; Macia M; Ruggenenti P
Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
[TBL] [Abstract][Full Text] [Related]
35. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
36. Aldosterone and the vasculature: mechanisms mediating resistant hypertension.
Duprez DA
J Clin Hypertens (Greenwich); 2007 Jan; 9(1 Suppl 1):13-8. PubMed ID: 17215650
[TBL] [Abstract][Full Text] [Related]
37. Serum-soluble (pro)renin receptor concentration as a biomarker for organ damage in primary aldosteronism.
Yamashita K; Morimoto S; Seki Y; Watanabe D; Ichihara A
Hypertens Res; 2019 Dec; 42(12):1951-1960. PubMed ID: 31409916
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Renin-Angiotensin-Aldosterone System to Prevent Hypertension and Kidney Disease of Developmental Origins.
Hsu CN; Tain YL
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669059
[TBL] [Abstract][Full Text] [Related]
40. Renal denervation attenuates aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension.
Hong MN; Li XD; Chen DR; Ruan CC; Xu JZ; Chen J; Wu YJ; Ma Y; Zhu DL; Gao PJ
Oncotarget; 2016 Oct; 7(42):67828-67840. PubMed ID: 27661131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
